T-Cell Lymphoproliferative Disorders Following Allogeneic Bone Marrow Transplant: A Report of Two Cases and a Literature Review.

Autor: Prabhakar N; Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, USA., Chiang H; Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, USA., Munoz Verdugo I; Internal Medicine, Advocate Christ Medical Center, Oak Lawn, USA., Hakimian A; Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, USA., Bufalino S; Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, USA., Bitran J; Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, USA.

Publikováno v: Cureus [Cureus] 2024 May 08; Vol. 16 (5), pp. e59901. Date of Electronic Publication: 2024 May 08 (Print Publication: 2024).

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Autor: Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigators, Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H.

Publikováno v: Ann Transl Med
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Summary Background Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f1362cea0664cfe2470bd04f49b410
https://hdl.handle.net/2318/1742132

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.

Autor: Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Canada., Armand P; Dana-Farber Cancer Institute, Boston, MA, USA., Hamadani M; Medical College of Wisconsin, Milwaukee, WI, USA., Kline J; Department of Medicine, University of Chicago, Chicago, IL, USA., Moskowitz CH; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Brody JD; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Ribrag V; Gustave Roussy, Villejuif, France., Herrera AF; City of Hope, Duarte, CA, USA., Morschhauser F; Department of Hematology, CHU Lille, Lille University, Lille, France., Kanate A; HonorHealth Cancer Transplant Institute, Scottsdale, AZ, USA., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy., Bitran J; Advocate Lutheran General Hospital, Park Ridge, IL, USA., Ghesquieres H; Lyon-Sud Hospital Center, Lyon, France., Schuster SJ; Department of Medicine, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Farooqui M; Merck & Co., Inc., Rahway, NJ, USA., Marinello P; Merck & Co., Inc., Rahway, NJ, USA., Bartlett NL; Siteman Cancer Center, Washington University, St. Louis, MO, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 130-139. Date of Electronic Publication: 2022 Nov 18.

Re: Intraoperative intracavernosal liposomal bupivacaine (Exparel) injection does not affect systemic hemodynamics.

Autor: Lokeshwar SD; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA., Hasanali SL; Medical College of Georgia, Augusta, GA, USA., Morera DS; Medical College of Georgia, Augusta, GA, USA., Bitran J; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA., Ramasamy R; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. ramasamy@miami.edu.

Publikováno v: International journal of impotence research [Int J Impot Res] 2021 Apr; Vol. 33 (3), pp. 378-379. Date of Electronic Publication: 2020 Mar 20.

Pulmonary AL amyloidosis: A review and update on treatment options.

Autor: Moy LN; Department of Internal Medicine at Advocate Lutheran General Hospital (ALGH), United States., Mirza M; Department of Internal Medicine at Advocate Lutheran General Hospital (ALGH), United States., Moskal B; Department of Internal Medicine at Advocate Lutheran General Hospital (ALGH), United States., Asado N; Department of Pathology at ALGH, United States., Shah B; Department of Pulmonology and Critical Care Medicine at ALGH, United States., Bitran J; Department of Hematology and Oncology at ALGH, United States.

Publikováno v: Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2022 Jul 08; Vol. 80, pp. 104060. Date of Electronic Publication: 2022 Jul 08 (Print Publication: 2022).